Immunoglobulin and Monoclonal Antibody Therapies in Guillain-Barré Syndrome.

Neurotherapeutics · 2022 · PMC9159039 · PMID 35648286

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

showed a trendno p-value reported

One immunoglobulin dose-comparative study (400 mg/kg daily given for 3 days versus, for 6 days) showed a trend for greater benefit in the prolonged treatment course in terms of median time taken to be able to walk with aid, but this result did not reach statistical significance [ 53 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.